New FDA Draft Guidance on Hematologic Malignancy and Oncologic Disease

Considerations for Use of Placebos and Blinding in Randomized Controlled Clinical Trials for Drug Product Development

This guidance provides recommendations to industry regarding the use of placebos and blinding in randomized controlled clinical trials in development programs for drug or biological products for the treatment of hematologic malignancies and oncologic diseases.

Read the pdf
Copyright Widler & Schiemann AG 2015. All Rights Reserved. /